Who
James Healy
Director
Company insider
Files Form 4 as: Director, BioAge Labs; Director, Rapport Therapeutics; Director, Seaport Therapeutics; Director, Y-mAbs Therapeutics; Director, Natera; Director, Bolt Biotherapeutics; Director, Karuna Therapeutics; Director, ArriVent BioPharma.
In numbers
- Trades disclosed
- 436
- Buys
- 29
- Sells
- 29
- Bought
- $180.3M
- Sold
- $120.3M
- Companies
- 22
- Companies where not an officer
- 22
- First trade
- 3 Jan 2006
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,927,159 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —804,379 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —6,052,631 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —6,052,631 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,526,315 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,526,315 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —1,927,159 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —804,379 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,222 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —8,000 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,000 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,950 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,545 | filing |
| 16 Sep 2025filed 18 Sep 2025 | Y-mAbs Therapeuticsoption or derivative | SEC FORM 4 Code D | —33,450 | filing |
News
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology | wallstreetONLINENTRA · wallstreet-online.de · 19 Oct 2026Curated Wealth Partners LLC Purchases 2,195 Shares of Natera, Inc. $NTRANTRA · dailypolitical.com · 16 Oct 2026BioAge Labs (NASDAQ:BIOA) & GSK (NYSE:GSK) Head-To-Head AnalysisBIOA · themarketsdaily.com · 16 Oct 2026Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026CHRS · manilatimes.net · 14 Oct 2026Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaOCGN · manilatimes.net · 14 Oct 2026Ocugen (NASDAQ:OCGN) Stock: Insider Shankar Musunuri Sells 468,727 SharesOCGN · tickerreport.com · 14 Oct 2026Natera, TransCode Target Residual Colorectal Cancer With Trial CollaborationNTRA · rttnews.com · 13 Oct 2026Amarin (NASDAQ:AMRN) and Merck KGaA (OTCMKTS:MKKGY) Financial ReviewAMRN · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name James Healy; 12 articles from the last 14 days about the 6 companies they traded most, at most three about any one of them.